UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Jan. 31, 2012	Jan. 31, 2011	Jan. 31, 2012	Jan. 31, 2011
Operating revenue:
Personalized oncology solutions	$ 649	$ 1,419	$ 1,837	$ 2,816
Translational oncology solutions	1,747	1,386	3,931	2,522
Total operating revenue	2,396	2,805	5,768	5,338
Costs and operating expenses:
Cost of personalized oncology solutions	528	725	1,463	1,213
Cost of translational oncology solutions	801	688	1,904	1,399
Research and development	930	434	2,558	2,117
Sales and marketing	623	239	1,885	356
General and administrative	1,287	1,505	4,421	2,649
Total costs and operating expenses	4,169	3,591	12,231	7,734
Loss from operations	(1,773)	(786)	(6,463)	(2,396)
Other income:
Grant income	(12)	367	(12)	1,327
Change in fair value of warrant liability	66	0	354	0
Other income	0	4	10	9
Total other income	54	371	352	1,336
Loss before provision for income taxes	(1,719)	(415)	(6,111)	(1,060)
Provision for income taxes	0	0	0	0
Net loss	$ (1,719)	$ (415)	$ (6,111)	$ (1,060)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	$ (0.04)	$ (0.01)	$ (0.13)	$ (0.03)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	46,738,000	35,664,000	47,000,000	35,693,000